Brave Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-5,724
| Closed | -$394K | – | 156 |
|
|
2021
Q2 | $394K | Sell |
5,724
-1,351
| -19% | -$90.2K | 0.12% | 89 |
|
|
2021
Q1 | $457K | Sell |
7,075
-100
| -1% | -$6.45K | 0.15% | 73 |
|
|
2020
Q4 | $418K | Hold |
7,175
| – | – | 0.16% | 74 |
|
|
2020
Q3 | $453K | Hold |
7,175
| – | – | 0.21% | 58 |
|
|
2020
Q2 | $552K | Sell |
7,175
-1,055
| -13% | -$80.9K | 0.29% | 48 |
|
|
2020
Q1 | $615K | Buy |
8,230
+2,500
| +44% | +$173K | 0.38% | 45 |
|
|
2019
Q4 | $372K | Hold |
5,730
| – | – | 0.19% | 86 |
|
|
2019
Q3 | $363K | Buy |
5,730
+500
| +10% | +$32.7K | 0.21% | 78 |
|
|
2019
Q2 | $353K | Buy |
5,230
+1,850
| +55% | +$122K | 0.2% | 81 |
|
|
2019
Q1 | $220K | Buy |
+3,380
| New | +$225K | 0.12% | 120 |
|
|
2018
Q4 | – | Sell |
-11,425
| Closed | -$882K | – | 156 |
|
|
2018
Q3 | $882K | Sell |
11,425
-350
| -3% | -$26.4K | 0.45% | 55 |
|
|
2018
Q2 | $834K | Sell |
11,775
-2,499
| -18% | -$176K | 0.48% | 59 |
|
|
2018
Q1 | $1.08M | Sell |
14,274
-3,320
| -19% | -$264K | 0.65% | 47 |
|
|
2017
Q4 | $1.26M | Sell |
17,594
-7,682
| -30% | -$583K | 0.66% | 49 |
|
|
2017
Q3 | $2.05M | Buy |
25,276
+19
| +0.1% | +$1.45K | 1.07% | 27 |
|
|
2017
Q2 | $1.8M | Sell |
25,257
-5,364
| -18% | -$357K | 0.96% | 27 |
|
|
2017
Q1 | $2.08M | Sell |
30,621
-2,778
| -8% | -$195K | 1.22% | 25 |
|
|
2016
Q4 | $2.39M | Buy |
33,399
+77
| +0.2% | +$5.72K | 1.53% | 17 |
|
|
2016
Q3 | $2.64M | Buy |
33,322
+4,575
| +16% | +$372K | 1.69% | 13 |
|
|
2016
Q2 | $2.4M | Buy |
28,747
+2,562
| +10% | +$227K | 1.6% | 15 |
|
|
2016
Q1 | $2.4M | Buy |
26,185
+1,755
| +7% | +$158K | 1.69% | 14 |
|
|
2015
Q4 | $2.47M | Buy |
24,430
+150
| +0.6% | +$15.6K | 1.67% | 12 |
|
|
2015
Q3 | $2.38M | Buy |
24,280
+5,255
| +28% | +$584K | 1.82% | 14 |
|
|
2015
Q2 | $2.23M | Buy |
19,025
+500
| +3% | +$54.6K | 1.56% | 14 |
|
|
2015
Q1 | $1.82M | Buy |
18,525
+8,720
| +89% | +$885K | 1.27% | 21 |
|
|
2014
Q4 | $924K | Buy |
9,805
+4,755
| +94% | +$492K | 0.66% | 49 |
|
|
2014
Q3 | $538K | Hold |
5,050
| – | – | 0.4% | 76 |
|
|
2014
Q2 | $419K | Buy |
5,050
+2,050
| +68% | +$160K | 0.3% | 96 |
|
|
2014
Q1 | $213K | Sell |
3,000
-200
| -6% | -$15.7K | 0.17% | 110 |
|
|
2013
Q4 | $240K | Buy |
+3,200
| New | +$223K | 0.19% | 101 |
|
Other funds holding GILD
Brave Asset Management's GILD Position: Q3 2021 in Review
Brave Asset Management sold out of Gilead Sciences (GILD) in Q3 2021, closing a stake of 5,724 shares — an estimated $394K sold.
Brave Asset Management first reported a position in GILD in Q4 2013 and held it in 30 quarters. The position peaked at $2.64M in Q3 2016. 1,564 funds tracked by Wall St. Rank hold GILD as of Q3 2021.
- Brave Asset Management reported no remaining Gilead Sciences position as of Q3 2021 after selling out during the quarter.
- Brave Asset Management sold 5,724 Gilead Sciences shares in Q3 2021, an estimated $394K.
- Brave Asset Management first reported a position in Gilead Sciences in Q4 2013 and held it in 30 quarters.
- Brave Asset Management's Gilead Sciences position peaked at $2.64M in Q3 2016.
- 1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.
Based on Brave Asset Management's 13F filing for Q3 2021, filed 2 Nov 2021.